Yarrow Bioscience Inc
- YARW
- NASDAQ
- Biotechnology
- Autoimmune Thyroid Therapies
- Antibody Therapeutics
$19.98
Today +9.12%Quote Oct 19, 2026, 08:00 PM UTC
−31.79%over the last month
Max drawdown −37.5%From 1-month high −31.8%3 months −55.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Yarrow Bioscience
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
10
Market value
$53.3M
Quote Oct 19
Analyst target
$5.75
−71.2% from here
Floor
$19.86
0.6% below price
Resistance
$21.40
7.1% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about YARWPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free